文献速递冠心病

氟-18 Flurpiridaz PET 评估冠心病的III期临床试验

Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

这项III期前瞻性多中心研究纳入795例已知或疑似冠心病患者,对比氟-18 Flurpiridaz PET与锝-99m SPECT检测ICA≥50%狭窄的诊断效能。Flurpiridaz PET灵敏度71.9%显著高于SPECT的53.7%,但特异度未达预设非劣效标准;在女性、肥胖及药物负荷患者中ROC曲线分析显示更优判别能力,且图像质量、诊断确定性及辐射暴露更佳。

要点

  • Flurpiridaz PET检测冠心病灵敏度71.9%,显著高于SPECT的53.7%
  • 特异度76.2%未达预设非劣效标准,SPECT为86.6%
  • 女性、肥胖及药物负荷患者中Flurpiridaz PET判别能力更优

核心结论

  • Flurpiridaz PET心肌灌注显像在冠心病检测中显示出作为新示踪剂的潜力,尤其在女性、肥胖患者及药物负荷患者中。

研究设计与样本

  • III期前瞻性多中心临床研究,纳入美国、加拿大和芬兰72个中心的795例已知或疑似冠心病患者,755例可评估,平均年龄62.3±9.5岁,31%为女性,55% BMI≥30 kg/m2,71%接受药物负荷。

主要发现

  • Flurpiridaz PET检测ICA≥50%狭窄的灵敏度为71.9%(95%CI 67.0%-76.3%),显著高于SPECT的53.7%(95%CI 48.5%-58.8%),p<0.001。
  • Flurpiridaz PET特异度为76.2%(95%CI 71.8%-80.1%),SPECT为86.6%(95%CI 83.2%-89.8%),未达预设非劣效标准(p=NS)。
  • ROC曲线分析显示Flurpiridaz PET在总体人群、女性、肥胖患者及药物负荷患者中判别冠心病优于SPECT(p<0.001)。
  • Flurpiridaz PET在缺损大小、图像质量、诊断确定性方面优于SPECT(p<0.001),辐射暴露为6.1±0.4 mSv,低于SPECT的13.4±3.2 mSv(p<0.001)。
  • Flurpiridaz PET安全且耐受良好。

关键数值与推荐

  • 冠心病定义为定量有创冠状动脉造影(ICA)显示≥50%狭窄。

临床怎么用

  • 对于已知或疑似冠心病患者,尤其是女性、肥胖及需药物负荷者,可考虑使用Flurpiridaz PET心肌灌注显像进行诊断评估。

局限性

  • Flurpiridaz PET特异度未达到预设的非劣效标准,需进一步评估其假阳性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fluorine-18 flurpiridaz is a novel positron emission tomography (PET) myocardial perfusion imaging tracer. OBJECTIVES: This study sought to assess the diagnostic efficacy of flurpiridaz PET versus technetium-99m-labeled single photon emission computed tomography SPECT for the detection and evaluation of coronary artery disease (CAD), defined as ≥50% stenosis by quantitative invasive coronary angiography (ICA). Flurpiridaz safety was also evaluated. METHODS: In this phase III prospective multicenter clinical study, 795 patients with known or suspected CAD from 72 clinical sites in the United States, Canada, and Finland were enrolled. A total of 755 patients were evaluable, and the mean age was 62.3 ± 9.5 years, 31% were women, 55% had body mass index ≥30 kg/m2, and 71% had pharmacological stress. Patients underwent 1-day rest-stress (pharmacological or exercise) flurpiridaz PET and 1- or 2-day rest-stress Tc-99m-labeled SPECT and ICA. Images were read by 3 experts blinded to clinical and ICA data. RESULTS: Sensitivity of flurpiridaz PET (for detection of ≥50% stenosis by ICA) was 71.9% (95% confidence interval [CI]: 67.0% to 76.3%), significantly (p < 0.001) higher than SPECT (53.7% [95% CI: 48.5% to 58.8%]), while specificity did not meet the prespecified noninferiority criterion (76.2% [95% CI: 71.8% to 80.1%] vs. 86.6% [95% CI: 83.2% to 89.8%]; p = NS). Receiver-operating characteristic curve analysis demonstrated superior discrimination of CAD by flurpiridaz PET versus SPECT in the overall population, in women, obese patients, and patients undergoing pharmacological stress testing (p < 0.001 for all). Flurpiridaz PET was superior to SPECT for defect size (p < 0.001), image quality (p < 0.001), diagnostic certainty (p < 0.001), and radiation exposure (6.1 ± 0.4 mSv vs. 13.4 ± 3.2 mSv; p < 0.001). Flurpiridaz PET was safe and well tolerated. CONCLUSIONS: Flurpiridaz PET myocardial perfusion imaging shows promise as a new tracer for CAD detection and assessment of women, obese patients, and patients undergoing pharmacological stress testing. A second phase III Food and Drug Administration trial is ongoing. (A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients with CAD; NCT01347710).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Maddahi J, Lazewatsky J, Udelson JE, et al. Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease. J Am Coll Cardiol. 2020. PMID: 32703509. doi:10.1016/j.jacc.2020.05.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。